Recce Pharmaceuticals higher on positive efficacy data in Murdoch Children’s Research Institute UTI study Posted on January 8, 2024September 25, 2024 by recce_com Recce Pharmaceuticals higher on positive efficacy data in Murdoch Children’s Research Institute UTI study
Recce Pharmaceuticals — Landmark commitment helps fund R&D costs Posted on December 22, 2023September 25, 2024 by recce_com Recce Pharmaceuticals — Landmark commitment helps fund R&D costs
Recce secures Australia’s largest-ever $11m Advanced Overseas R&D Finding Posted on December 20, 2023September 25, 2024 by recce_com Recce secures Australia’s largest-ever $11m Advanced Overseas R&D Finding
Recce Pharmaceuticals awarded A$11 million Advanced Overseas Finding for anti-viral R&D costs Posted on December 17, 2023September 25, 2024 by recce_com Recce Pharmaceuticals awarded A$11 million Advanced Overseas Finding for anti-viral R&D costs
Recce Pharmaceuticals awarded $43.7 million Advanced Overseas Finding for synthetic anti-infective development program Posted on December 15, 2023September 25, 2024 by recce_com Recce Pharmaceuticals awarded $43.7 million Advanced Overseas Finding for synthetic anti-infective development program
Recce Pharmaceuticals lead anti-infective R327 shows promise against deadly STD in latest animal study Posted on December 14, 2023September 25, 2024 by recce_com Recce Pharmaceuticals lead anti-infective R327 shows promise against deadly STD in latest animal study
Antimicrobial resistance with Recce Pharmaceuticals Posted on December 6, 2023September 25, 2024 by recce_com Antimicrobial resistance with Recce Pharmaceuticals
Engineering the future of antibiotics Posted on December 6, 2023September 25, 2024 by recce_com Engineering the future of antibiotics
Recce Pharmaceuticals wins Canadian patent for flagship anti-infectives Posted on November 23, 2023September 25, 2024 by recce_com Recce Pharmaceuticals wins Canadian patent for flagship anti-infectives
Recce Pharmaceuticals doses first patients over 15 minutes in R327 UTI/urosepsis trial Posted on November 7, 2023September 25, 2024 by recce_com Recce Pharmaceuticals doses first patients over 15 minutes in R327 UTI/urosepsis trial
